/PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative...
null
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology,...
null
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative...
null
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology...
null
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business...
null
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the...
null
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding...
#Product Stage #Acquisition #Investment
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel...
#Investment #Acquisition #Partners
דוח של UBS חושף את ההשלכות הכלכליות המשמעותיות של השקעה בבריאות האישה; חברת Scinai רוכשת את המפעל הישראלי של רציפארם השבדית; סטארגט פארמה גייסה מיליוני דולרים לקידום תרופה רדיואקטיבית; יחסי בריטניה-ישראל בתחום המחקר הרפואי מתהדקים; ואתר חדש ירכז משרות בתחום מדעי החיים ● השבוע בביומד
#Acquisition #Management Changes #Expand
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology...
#Acquisition #Partners
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
null
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology...
undefined
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and...
#Product Stage #Partners #Investment
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company with a growing boutique contract...
#Investment
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and...
#Investment #Partners #Product Stage
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
#Investment #Partners #Customers
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering...
#Investment #Partners #Customers
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
#Acquisition
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological...
#Acquisition
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and...
#Product Stage #Investment
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
#Product Stage #Investment
Scinai Announces Annual Financial Results for 2024
#Product Stage #Customers
Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
#Acquisition #Product Stage
Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating...
#Product Stage #Acquisition #Investment
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
#Product Stage #Acquisition
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
#Partners #Investment
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological...
undefined
SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT
#Investment
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
#Partners #Investment
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
#Partners #Expand
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
#Customers #Partners
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
#Management Changes
There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability
undefined
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
#Management Changes
/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
#Management Changes
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
#Investment
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
#Partners
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
undefined
Scinai Regains Full Compliance with Nasdaq Listing Requirements
#Investment
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
#Investment
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
#Investment
Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23
#Investment #Partners
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
#Investment
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
#Customers #Management Changes
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model
#Investment #Expand
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
#Investment
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
#Public Trading
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
#Investment #Expand
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
#Investment
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement
#Investment #Public Trading
Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance
#Investment #Public Trading
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update
#Investment #Expand
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
#Public Trading #Management Changes
Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
#Partners
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
#Partners #Customers
Scinai leadership to attend BIO-Europe Spring 2024
#Partners #Customers #Investment
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
#Customers #Partners
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
#Management Changes #Expand
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize
#Partners
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
#Investment #Expand
Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
#Investment
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
#Investment
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
#Management Changes
Scinai Announces Promising Results in a Psoriatic Human Skin Model
#Customers #Partners #Expand
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug
#Partners #Customers
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
#Investment #Partners
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031
#Investment #Partners
Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule
#Investment #Public Trading
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
#Investment #Expand
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
#Investment
European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
#Investment
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
#Investment, Management Changes
Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
#Partners
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
#Partners, Expand
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
#Investment
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
#Investment
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
#Investment #Partners
Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
#Investment #Partners
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
#Management Changes #Expand
BiondVax Reports Second Quarter Financial Results and Provides Business Update
#Investment #Management Changes
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
#Partners #Expand
BiondVax bets on alpacas to treat psoriasis
#Investment #Management Changes #Expand
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
#Investment #Expand
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
#Partners #Expand
BVXV: Developing anti-IL-17 NanoAb
#Partners #Expand
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
#Investment
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
#Partners #Investment
BiondVax to Present at BIO-Europe Spring
#Partners, Expand
IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman
#Partners #Investment #Management Changes
IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes
#Investment #Management Changes
BiondVax Presenting at BIO CEO & Investor Conference
#Management Changes #Expand
BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate
#Investment #Expand
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
#Investment #Expand
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
#Investment, Expand
BiondVax to Present at Biotech Showcase 2023
#Partners #Investment
BiondVax CEO Issues Letter to Shareholders
#Partners #Investment #Expand
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)
#Investment #Public Trading
BiondVax Announces Closing of $8 Million Underwritten Public Offering
#Investment #Public Trading
BiondVax Announces Pricing of $8 Million Underwritten Public Offering
#Investment #Public Trading
BiondVax Regains Nasdaq Compliance
#Public Trading
BVXV: Positive Preclinical Results for Inhaled COVID-19 NanoAb…
#Investment, Expand
IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.
#Partners #Expand
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
#Management Changes #Partners
BiondVax to present at LD Micro Investor Conference in Los Angeles
#Investment
BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19
#Partners #Expand
BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies...
#Partners #Investment
BiondVax Announces Pricing of $9.0 million Follow-on Underwritten Offering of American Depositary Shares
#Investment #Public Trading
BiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany
#Partners #Expand
ביונדווקס חוזרת אחרי קריסת המניה: "מחפשים לפתח חיסונים חדשים"
#Management Changes #Investment
BiondVax Announces Appointment of Amir Reichman as New CEO
#Management Changes
Biondvax plunges on failed universal flu vaccine trial
#Investment
BiondVax Announces At-The-Market (ATM) Equity Offering Program
#Investment
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
#Investment #Expand
Flu Season Might Soon Pass, for Good
#Investment, Expand
Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax
#Investment
First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
#Customers, Expand
aMoon expands investment in BiondVax
#Investment
EIB grants BiondVax €4m for universal flu vaccine
#Investment
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference
#Management Changes, Expand
http://www.biondvax.com/2018/09/biondvax-to-present-at-influenza-2018-oxford-conference/
undefined
Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange
#Public Trading #Management Changes
BiondVax Receives Additional Grant Funding
#Investment
Marius Nacht fund invests NIS 10.9m in BiondVax
#Investment #Partners
BiondVax Invited to WHO Influenza Vaccine Meeting
#Partners
A vaccine that will eliminate flu
#Investment #Expand
Flu vaccine co Biondvax raises $9.5m in Nasdaq IPO
#Investment, Public Trading
BiondVax Receives $1.3M Grant From Chief Scientist
null